I		
	2	
	3	
Elena Vacc	4	
Francesco Ma	5	
	6	
	7	
1. 1 Laborator	8	
Ospedaliero Ca	9	
2. 2 Faculty of	10	
3. 3 Laboratory	11	
Cantonale, Lug	12	
4. 4 Neurology	13	4
Lugano, Switze	14	.202
5. 5 Neurosur	15	28.4
Cantonale, Lug	16	ded:
6. 6 Institute of	17	wnloa
7. 7 Departmen	18	qo
Switzerland	19	640
	20	50/169
Correspondence	21	L0.483
Laboratory for	22	rg/]
Ospedaliero Ca	23	doi.c
E-mail: giorgia	24	//:sd:
Running title:	25	: htt
© The Author(s) 2 reserved. For perm under the terms of		source

1

## Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies

## chi,<sup>1,2</sup> Edoardo Lazzarini,<sup>3</sup> Sandra Pinton,<sup>1</sup> Giacomo Chiaro,<sup>1,4</sup> Giulio Disanto, urchi,<sup>5</sup> Thomas Robert,<sup>2,5</sup> Claudio Staedler,<sup>4</sup> Salvatore Galati,<sup>2,4</sup> Claudio Gobbi,<sup>2,4</sup> Lucio Barile,<sup>2,3,6</sup> Alain Kaelin-Lang<sup>1,2,4,7</sup> and Giorgia Melli<sup>1,2,4</sup>

y for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente

intonale, Lugano, Switzerland

Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland

v for Cardiovascular Theranostics, Cardiocentro Ticino Institute, Ente Ospedaliero ano, Switzerland

Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, erland

Neurocenter of Southern Switzerland, Ente Ospedaliero gery Department, ano, Switzerland

f Life Science, Scuola Superiore Sant'Anna, Pisa, Italy

nt of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern,

#### e to: PD Dr Med Giorgia Melli

r Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente antonale, via Francesco Chiesa 5, 6500 Bellinzona, Switzerland

.melli@eoc.ch

#### Tau protein in skin biopsy

2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights nissions, please e-mail: journals.permissions@oup.com This article is published and distributed the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model) 1

## 1 Abstract

Abnormal accumulation of microtubule-associated protein tau ( $\tau$ ) is a characteristic feature of atypical parkinsonisms with tauopathies such as Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD). However, pathological  $\tau$  has also been observed in  $\alpha$ synucleinopathies like Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Based on the involvement of peripheral nervous system in several neurodegenerative diseases, we characterized and compared  $\tau$  expression in skin biopsies of patients clinically diagnosed with PD, MSA, PSP, CBD, and in healthy control subjects.

In all groups,  $\tau$  protein was detected along both somatosensory and autonomic nerve fibers in the 9 epidermis and dermis by immunofluorescence. We found by western blot the presence of mainly 10 two different bands at 55 and 70 KDa, co-migrating with 0N4R/1N3R and 2N4R isoforms, 11 respectively. At the RNA level, the main transcript variants were 2N and 4R, and both resulted 12 more expressed in PSP/CBD by real-time PCR. ELISA assay demonstrated significantly higher 13 levels of total  $\tau$  protein in skin lysates of PSP/CBD compared to the other groups. Multivariate 14 15 regression analysis and ROC curves analysis of  $\tau$  amount at both sites showed a clinical association with tauopathies diagnosis and high diagnostic value for PSP/CBD vs. PD 16 17 (sensitivity 90%, specificity 69%) and PSP/CBD vs. MSA (sensitivity 90%, specificity 86%).  $\tau$ 18 protein increase correlated with cognitive impairment in PSP/CBD.

19 This study is a comprehensive characterization of  $\tau$  in the human cutaneous peripheral nervous 20 system in physiologic and pathologic conditions. The differential expression of  $\tau$ , both at 21 transcript and protein levels, suggests that skin biopsy, an easily accessible and minimally 22 invasive exam, can help in discriminating among different neurodegenerative diseases.

23 Keywords: tau protein; skin biopsy; Parkinson's disease; tauopathies; biomarkers.

Abbreviations: AUC = Area under the curve; BDI-II = Beck Depression Inventory-II; BTubIII = 24 Beta Tubulin III; COMPASS-31 = Composite Autonomic Symptom Score 31; CI = Confidence 25 intervals; CBD = Corticobasal degeneration; HC = Healthy control; H&Y = Hoehn and Yahr 26 Scale; IF = Immunofluorescence; IENFD = Intraepidermal nerve fiber density; LEDD = 27 Levodopa equivalent daily dose; LDA = Linear Discriminant Analysis; MMSE = Mini-Mental 28 29 State Examination; MoCA = Montreal Cognitive Assessment; MDS-UPDRS = Movement Disorder Society Unified Parkinson's Disease Rating Scale; MSA = Multiple system atrophy; 30 MAP = Muscle arrector pili; OR = Odds ratios; o.n. = Over night; PD = Parkinson's disease; 31 32 PCR = Polymerase Chain Reaction; PSP = Progressive supranuclear palsy; PGP9.5 = Protein gene product 9.5; ROC = Receiver operating characteristics; RBD = REM sleep Behavior 33 Disorder; RT = Room Temperature; SbG = Sebaceous Gland; SG = Sweat glands;  $\tau$  = Tau 34 protein; Wb = Western Blot. 35

#### 1 Introduction

Tau ( $\tau$ ) is a microtubule-associated protein coded by *MAPT* gene<sup>1</sup>. In the adult human central 2 nervous system, post-transcriptional modifications of  $\tau$  pre-mRNA can produce six different 3 mature mRNA molecules: 0N3R, 0N4R, 1N3R, 1N4R, 2N3R, 2N4R<sup>1</sup>. Such isoforms result from 4 the combination of alternative splicing of exons 2 and 3, generating the amino-terminal inserts 5 0N, 1N, and 2N, and alternative splicing of exon 10 coding for three or four carboxy-terminal 6 repeat domains named respectively 3R and  $4R^1$ .  $\tau$  is also subjected to several post-translational 7 modifications<sup>2,3</sup>, such as phosphorylation<sup>4</sup>, acetylation<sup>5</sup>, and ubiquitination<sup>6</sup>, which strongly 8 regulate its function. Mutations in the MAPT gene or abnormalities in post-translational 9 regulatory mechanisms can induce  $\tau$  aggregations and toxicity; for instance, hyper-10 phosphorylation in different sites of  $\tau$  seems to precede and enhance aggregation<sup>7-9</sup>. Although the 11 presence of mutated and/or aggregated  $\tau$  in the brain is the hallmark of a family of 12 neurodegenerative diseases called tauopathies<sup>10</sup>, such as Alzheimer's disease, Progressive 13 Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD), pathological  $\tau$  has also been 14 observed in synucleinopathies at later stages like Parkinson Disease (PD)<sup>11</sup> and multiple system 15 atrophy (MSA)<sup>12,13</sup>. 16

Previous studies have demonstrated the presence of hyper-phosphorylated  $\tau$  in tauopathies 17 patients' peripheral tissues like olfactory<sup>14</sup> and oral<sup>15</sup> epithelium and colon specimens<sup>16</sup>, boosting 18 the possibility to use peripheral tissues not only for research but also as a diagnostic tool. Due to 19 its easy, minimally-invasive accessibility and its great content in nerve fibers, skin is a candidate 20 for biomarkers discovery in neurodegenerative disorders<sup>17</sup>. Indeed, skin biopsy has already been 21 exploited to detect  $\alpha$ -Synuclein, the pathological hallmark of PD, in patients with 22 synucleinopathies<sup>18-20</sup> and to demonstrate and quantify a small fiber neuropathy in PD by 23 intraepidermal nerve fiber density (IENFD) measurement<sup>20-22</sup>. 24

Nevertheless, few studies have explored the expression of  $\tau$  in peripheral tissues and skin<sup>23-26</sup>; in particular, a comprehensive investigation of  $\tau$  in human skin in physiological and pathologic conditions is lacking. Thus, the aims of this study were to: 1) assess the presence of total and phosphorylated forms of  $\tau$  in skin biopsy from HC and patients clinically diagnosed with PD, MSA, and PSP/CBD; 2) quantitatively analyze differences in  $\tau$  expression among groups; 3) evaluate the diagnostic capacity of cutaneous  $\tau$  for PD, MSA, and PSP/CBD.

## 1 Materials and methods

#### 2 Subjects' recruitment

Patients were consecutively recruited from the movement disorders outpatient clinic at NSI
Lugano from July 2015 to October 2021. HC were recruited among hospital staff and patients'
partners as part of the NSIPD001 study<sup>20</sup>.

6 Inclusion criteria for PD were: a definite clinical diagnosis according to the UK Brain Bank 7 diagnostic criteria<sup>27</sup>, no family history, and no significant cognitive impairment or dysautonomic 8 symptoms in the history. The inclusion criteria for MSA<sup>28</sup>, PSP<sup>29</sup>, and CBD <sup>30</sup> were based on 9 published diagnostic criteria. Exclusion criteria were significant comorbidities diabetes, renal 10 failure, thyroid pathology, vitamin B12 deficiency, HIV infection, syphilis, coagulopathy, acute 11 and chronic inflammatory diseases, and chemotherapy.

This study was performed in line with the principles of the Declaration of Helsinki. Subjects were included according to the study protocol, approved by the Cantonal Ethics Committee. All enrolled subjects gave written informed consent to the study.

#### 15 Clinical assessments

PD, MSA, PSP, and CBD patients underwent a standard clinical evaluation: disease gravity was 16 assessed by Hoehn and Yahr scale (H&Y)<sup>31</sup> and the Movement Disorder Society-Unified 17 Parkinson's Disease Rating Scale<sup>32</sup> (scale I - clinical evaluation of mental state, behaviour, and 18 mood; scale II - self-assessment by the patient of specific daily activities; scale III - clinical 19 evaluation of motor skills); cognitive profile by Mini-Mental State Evaluation (MMSE)<sup>33</sup> and 20 Montreal Cognitive Assessment (MoCA)<sup>34</sup> scales; mood disorder by Beck Depression Inventory-21 II (BDI-II) scale<sup>35</sup>; autonomic dysfunction by Composite Autonomic Symptom Score 31 22 (COMPASS-31, OH: orthostatic hypotension, VM: vasomotor, SM: sudomotor, GI: 23 gastrointestinal, BL: bladder, PM: pupillomotor)<sup>36</sup>; Rapid eve movement sleep Behavior 24 Disorder (RBD) by RBD screening questionnaire<sup>37</sup>; olfactory function by Sniffin' Sticks Smell 25 test (Burghart Messtechnik GmbH, Wedel, Germany). Levodopa equivalent daily dose (LEDD) 26 was calculated<sup>38</sup>. 27

#### 1 Skin biopsy

On the more clinically affected side, a double three mm-diameter punch skin biopsy was
performed in the neck at C8 dermatomal level (cervical) and in the distal leg 10 cm above lateral
malleolus (ankle)<sup>20,39</sup>. For each anatomical site, one biopsy was fixed for immunofluorescence
(IF) studies<sup>20,22,39</sup>, and one biopsy was stored at -80° until further analysis by Western blot (Wb),
ELISA, or Polymerase Chain Reaction (PCR) assays.

#### 7 Immunofluorescence

IF assays were performed as previously described<sup>20,22,39</sup>. Briefly, skin biopsies were fixed 8 overnight (o.n.) at 4°C in Paraformaldehyde-Lysine-Periodate 2% fixative. The day after, they 9 were frozen and cut with a cryotome to obtain 50 µm-thin tissue sections for free-floating 10 immunofluorescence analysis. Three non-consecutive sections per biopsy were incubated o.n. at 11 room temperature (RT) with a panel of primary antibodies (Table 1). The day after, sections 12 were washed twice in tris-buffered saline (TBS; ThermoFisher Scientific, Waltham USA) for 10 13 minutes at RT and incubated with the appropriate fluorescence-tagged secondary antibody 14 (Table 1) for 90 minutes at RT. Cell nuclei were counterstained with 4',6-diamidino-2-15 phenylindole (DAPI, Sigma-Aldric h, Saint Louis USA, 1:5000). Sections were viewed and 16 analyzed with a Nikon confocal microscope (40x magnification, successive frames of 2µm 17 increments on a Z-stack plan) using NIS Elements 4.11.01 imaging software. 18

### 19 Intraepidermal nerve fiber density

Intraepidermal nerve fiber density (IENFD) was assessed as a measure of small fiber 20 neuropathy<sup>40-43</sup>. At least three tissue sections per localization per patient were stained with the 21 primary antibody against Protein Gene product 9.5 (PGP9.5, Abcam, Cambridge UK, 1:1000). 22 PGP9.5 positive nerve fibers crossing the dermal-epidermal junction were counted. The length of 23 the section was measured using NIS Elements 4.11.01 imaging software (Tool: manual 24 measure). IENFD was obtained by dividing the number of fibers by the length of the section and 25 expressed as the "number of fibers/mm". IENFD was determined at both ankle and cervical sites, 26 and total IENFD was calculated as the mean of nerve densities at both localizations $^{22}$ . 27

#### 1 Western blot

2 Skin biopsies from HC (n=20), PD (n=26), MSA (n=9), and PSP/CBD (n=10) were 3 homogenized in 1mL of radioimmunoprecipitation assay buffer (RIPA; Sigma Aldrich, Saint Louis, USA) supplied with protease inhibitor (Sigma Aldrich, Saint Louis, USA, 1:10) and used 4 5 for Wb and ELISA assays. After centrifugation at 13000 rpm for 3 minutes, supernatants were 6 analyzed. Protein quantification was determined with the QuantiPro BCA assay kit (Sigma 7 Aldrich, Saint Louis, USA). Proteins were separated on SDS-PAGE 12% acrylamide gel and transferred onto PVDF membranes, which were subsequently incubated with a panel of primary 8 9 antibodies (Table 1) o.n. at 4°C. After three washing in TBS-Tween 0.1% incubation with secondary antibody for 90 minutes was performed at RT (Table 1). The membranes were 10 11 analyzed with the Odyssey CLx system (Li-cor Biosciences, Lincoln, Nebraska). Phosphorylated  $\tau$  quantification in skin extracts was performed by an expert, blind to the clinical diagnosis, with 12 IS Image studio software Ver 5.0. The intensity of the two bands at 70kDa and 55kDa was 13 normalized to the  $\beta$ -actin signal. The sum of the two bands was calculated for each patient and 14 each localization. 15

#### 16 ELISA

Homogenized samples were diluted at 1:20 in PBS 1x (ThermoFisher Scientific, Waltham, 17 USA). 50 µL of diluted sample per well were put in a coated 96 well-plate (Nunc MaxiSorp, 18 19 ThermoFisher Scientific, Waltham, USA), o.n at 4°C. Subsequently, samples were washed three times with PBS-Tween 0.05% and then incubated with: blocking buffer (PBS-Tween 0.05%, 20 21 Bovine Serum Albumin 1%) for 1h at 37°C; primary antibody (unphosphorylated and phosphorylated at Ser262 human Tau, 1:500; Table 1) for 1h at 37°C; secondary antibody (Goat 22 anti-Rabbit HRP, Biorad, Hercules USA, 1.5000) for 1h at 37°C. 50 µL of TMB-Substrate 23 24 (ThermoFisher Scientific, Waltham USA) were added to each well, and absorbance (450nm) was 25 measured immediately after adding the stop solution (Phosphoric Acid 2M) by Infinite M-PLEX TECAN instrument (Männedorf, Switzerland).  $\tau$  concentration was normalized to the sample 26 protein concentration (QuantiPro BCA assay kit). 27

#### **1 RNA extraction and reverse transcription**

Skin biopsies from HC (n=4), PD (n=5), MSA (n=5), PSP (n=4)/CBD (n=1) were homogenized 2 3 in 1mL of TRIzol (ThermoFisher Scientific, Waltham USA). A smaller cohort was analyzed based on the tissue availability in the bio-bank of the NSIPD001 study (demographic and clinical 4 5 characteristics are summarized in Supplementary Table 1). As a positive control for PCR assays, 6 we analyzed a little cortical sample from a patient without a neurodegenerative disorder who 7 underwent a craniotomy for diagnostic purposes after obtaining informed consent. 250µL of chloroform (Sigma Aldrich, Saint Louis, USA) was added to the homogenate, which was 8 9 subsequently centrifuged at 10.000 rpm for 5 minutes. The aqueous phase was transferred to a new sterile tube containing 550µL of isopropanol (Sigma Aldrich, Saint Louis, USA). Samples 10 were kept at RT for 5 minutes, followed by 1hour at -80°. Next, samples were centrifuged at 11 14.000 rpm for 20 minutes; the supernatant was discharged and substituted with 500µL of 75% 12 ethanol (Sigma Aldrich, Saint Louis, USA). Ethanol was removed after centrifugation at 9.500 13 rpm for 5 minutes, and pellets were resuspended in 20µL of pure water. The total RNA 14 quantification of samples was determined by Nanodrop 200 Spectrophotometer (ThermoFisher 15 Scientific, Waltham, USA). 800ng of total RNA were reverse transcribed into cDNA with 16 GoScript<sup>™</sup> Reverse Transcription System (Promega Corporation, Madison USA), following the 17 manufacturer's protocol. The resulting cDNA was stored at -20 °C until use. 18

#### 19 PCR assay

PCR was performed using the Dream-Taq DNA polymerase (ThermoFisher Scientific, Waltham 20 21 USA) following manufacturer protocol, the annealing temperature was set at  $60^{\circ}$ , and 35 reaction cycles were performed. To examine the alternate splicing of exons 2 and 3 at the N-terminal 22 domain of  $\tau$ , the cDNA was amplified using the primers for exon 1 (F 5'-23 5'-ACACGGACGCTGGCCTGAAA-3') 4 (R 24 and exon 25 TCACGTGACCAGCAGCTTCGTCTT-3'). To evaluate the splicing of exon 10 in the microtubule-binding domain repeat region, the cDNA was amplified using the primers for exon 9 26 (F (R 5'-27 5'-CAGTGGTCCGTACTCCACCCAA-3') and 11 exon TGGTTTATGATGGATGTTGCCTAATGAG-3'). GAPDH gene was used as a housekeeper 28 29 and amplified with the primers: F 5'- TGCACCACCAACTGCTTAGC-3' and R 5'-

GGCATGGACTGTGGTCATGAG-3'. Primers were designed with the primer design tool
 PrimerBlast (NCBI).

The resulting PCR products were separated by 2,5% Tris-acetate-EDTA agarose gel electrophoresis. Obtainable bands were 2N amplicon of 255 base pairs (bp), 1N and 0N of respectively 168bp, and 81bp length, 4R and 3R of respectively 317bp and 224bp. *GAPDH* amplicon was 87 bp.

#### 7 Real-time PCR

Real-time PCR was performed using SsoAdvanced Universal SYBR Green Supermix (Biorad,
Hercules USA), following the manufacturer's instructions in triplicate. *MAPT* gene was
amplified with two different pairs of primers published on Primerbank: F 5'CCAAGTGTGGGCTCATTAGGCA-3', R 5'-CCAATCTTCGACTGGACTCTGT-3', and F 5'GAGTCCAGTCGAAGATTGGGT-3', R 5'-GGCGAGTCTACCATGTCGATG-3'.

The 2N splicing variants of the MAPT gene were amplified using the primers for exon 3 (F 5'-13 TGACAGCACCCTTAGTGGATGA-3') and 5'-4 (R 14 exon TCACGTGACCAGCAGCTTCGTCTT-3'); while the 4R splicing variants were amplified using 15 the primers for exon 9 (F 5'-CAGTGGTCCGTACTCCACCCAA-3') and a primer spanning the 16 exon 9 and 10 (R 5'-AGCTTCTTATTAATTATCTGCACCTTC-3'). Primers were designed 17 with PrimerBlast tool (NCBI). RPL27 gene was amplified as endogenous controls for 18 normalization (F 5'-TGGTAGGGCCGGGTGGTTGC-3': 5'-R 19 ACTTTGCGGGGGTAGCGGTC-3'). The PCR reaction was carried out on CFX-Connect real-20 time PCR Detection System (Biorad, Hercules USA):  $\tau$  cDNA expression was calculated by 21  $\Delta\Delta Ct$  methods as previously reported<sup>44</sup>. The real-time PCR was performed in triplicate, pooling 22 together samples of subjects of the same group. Sample pools were obtained by loading the same 23 24 amount of cDNA from every sample, and the same quantity of cDNA pools per group was 25 loaded for real-time PCR amplification. Values were normalized to the mean of  $\tau$  cDNA expression of HC at the ankle and cervical sites. 26

#### **1** Statistical Analysis

Statistical analysis was performed using IBM SPSS Statistics 26.0. The distribution of variables 2 3 was assessed by the Kolmogorov-Smirnov test. 1-way ANOVA test with post-hoc Bonferroni's test for multiple comparisons was used for normally distributed variables (age), expressed as 4 5 mean ± standard deviation. Kruskal-Wallis test was used for non-normally distributed variables (disease duration, H&Y, MDS-UPDRS, BDI-II, MMSE, MoCA, COMPASS-31, Olfactory test, 6 7 RBD, LEDD, Tau concentration, IENFD), expressed as medians and interquartile range.  $\chi^2$  or Fisher's exact tests were used for categorical variables (sex), defined as a percentage (%). 8 9 Univariate and multivariate logistic regression was used to test compound  $\tau$  for association with disease status (PSP/CBD vs. all other groups and PSP/CBD vs. MSA/PD), with odds ratio and 10 11 95%CI intervals calculation. Receiver operating characteristics (ROC) curves analysis was used to evaluate the area under the curve (AUC) and compare selected variables' diagnostic 12 performances. Younden index (J = Sensitivity + Specificity -1) was calculated to determine the 13 cut-off with greater accuracy. For Linear Discriminant Analysis (LDA), canonical components 1 14 and 2 were calculated from weighted linear combinations of variables to maximize separation 15 between the four groups (HC, PD, MSA, PSP/CBD); in the plot, each patient is represented by a 16 point, the centroid indicates the mean of (canonical 1 and canonical 2) for each diagnosis. 17 Correlations were evaluated by Pearson's R test and regression curve analysis; correlations were 18 considered strong for R between [1.0] and [0.5], moderate between [0.5] and [0.3], weak between 19 [0.3 and [0.1]. A P-value lower than 0.05 was considered significant. 20

## 21 Data availability

The raw data that support the findings of this article are available on request to the correspondingauthor.

## 24 **Results**

#### 25 **Patients**

Thirty-one patients with idiopathic PD, 14 with probable MSA, 15 PSP/CBD (11 probable PSP, 4 possible CBD), and 24 age-matched HC for the PD group were enrolled. The demographic

characteristics and clinical assessments of the study groups are summarized in Table 2. Sex ratio 1 2 did not differ across all groups; while disease duration did not differ across patients; PSP/CBD 3 subjects were significantly older than HC. MSA and PSP/CBD patients had a more severe disease burden than PD, as measured by H&Y and MDS-UPDRS scales, and a higher cognitive 4 impairment as measured by MMSE. PSP/CBD subjects were more depressed than PD as 5 measured by the BDI-II scale and showed a more severe cognitive impairment than both PD and 6 7 MSA, as assessed by MoCA. Finally, MSA patients had greater autonomic impairment in genitourinary function than PD and PSP/CBD, as measured by the COMPASS-31 questionnaire 8 (bladder [BL] subdomain). No significant difference in LEDD was detected among groups. 9

#### 10 $\tau$ protein is expressed in epidermal and dermal nerve fibers

The presence of  $\tau$  protein in skin biopsies of HC at both anatomical sites was assessed by IF 11 assays with several primary Abs against different epitopes of  $\tau$  (Table 1 and Fig. 1A): the N-12 terminal region (Tau13), the proline-rich domain (HT7 and Tau5), and the tubulin-binding region 13 (Tau). They all showed clear immunoreactivity along cutaneous nerve fibers (Fig. 1B) 14 counterstained with the panaxonal markers PGP 9.5 or Beta Tubulin class III (BTubIII). T 15 positive nerve fibers were found in the epidermis, dermis, and autonomic structures such as 16 17 sweat glands (SG), sebaceous glands (SbG), and muscle arrector pili (MAP). Indeed, the colocalization of  $\tau$  with a specific cholinergic marker (vasoactive intestine peptide, VIP) and 18 adrenergic marker (tyrosine Hydroxylase, TH) confirmed the presence of  $\tau$  in autonomic nerve 19 fibers as well (Fig. 1C). 20

 $\tau$  protein was detected in skin biopsies from ankle and cervical sites in PD, MSA, and PSP/CBD (Fig. 2). Overall, qualitative IF analysis showed high levels of τ in the PSP/CBD group, especially at the cervical site and in both intraepidermal somatosensory fibers and autonomic fibers surrounding SG, SbG, and MAP. Finally, we tested several Abs against different phosphorylated epitopes of τ by IF (Table 1): Threonine212 (pThr212), Serine262 (pSer262), Serine396 (pSer396), Serine404 (pSer404). However, we did not detect a positive signal in the skin by IF.

#### 1 Two $\tau$ isoforms and phosphorylated $\tau$ are present in skin

To analyze  $\tau$  isoforms expressed in skin lysates at the ankle and cervical sites, samples (10 subjects per HC, PD, PSP/CBD, and 9 for MSA) were tested with Tau and Tau13 antibodies (Table 1, Fig. 3A-B) and compared to human recombinant tau ladder (Sigma-Aldrich, Saint Louis USA, 1:5000). In skin lysate, two major bands were displayed with both antibodies: one at 55kDa, which co-migrated with 0N4R/1N3R isoform, and one at 70kDa corresponding to the 2N4R isoform. Big-tau, the high molecular weight isoform of  $\tau$  identified in peripheral nerves, was not detected in the skin.

9 In all groups pThr212, pSer262, and pSer404 Abs detected both bands at 55 kDa and 70 kDa at 10 the ankle and cervical sites (Fig. 3F, G, I), while pSer396 Ab detected mainly the band at 70kDa 11 (Fig. 3H). In all subjects, phosphorylated  $\tau$  resulted more abundant at the cervical site by 12 semiquantitative analysis of bands intensity (*P*=0.001), while no significant difference was found 13 between groups. As a negative control, Abs for phosphorylated forms of  $\tau$  did not mark the un-14 phosphorylated isoforms of human recombinant  $\tau$  (Tau ladder, Fig. 3F-I).

#### 15 2N and 4R mRNAs are more expressed in PSP/CBD

The analysis of the alternative splicing by PCR showed the presence of the 2N variant in skin samples and a lower amount of 1N, while the 0N was never observed. Regarding the splicing at C-terminal, we observed mainly the 4R and, in some cases, a fainter 3R isoform mainly in HC and PD. Therefore, according to PCR results, the main transcript variants were 2N and 4R (Fig. 3C).

The quantification by real-time PCR of *MAPT* gene in skin showed, as expected, a reduced expression compared to the brain and a trend in reduced expression in cervical skin compared to the ankle in PD but no significant difference among and within groups (Fig. 3D). Since we observed mainly the 2N and 4R by PCR assay, we performed the real-time PCR considering primers specific for these isoforms (Fig. 3E-F). The 2N transcript was higher at the cervical than ankle, and while PD and MSA showed similar levels to HC, the PSP/CBD group displayed a major increase of the 2N variant at both anatomical sites compared to the other groups and also compared to the brain control. The 4R transcript showed a similar level at both anatomical
 regions and, similarly to 2N, an increase in the PSP/CBD group.

#### 3 Skin total $\tau$ concentration is a biomarker for PSP/CBD diagnosis

4 The amount of total  $\tau$  protein was quantified by ELISA assay using Tau Ab, which targets un-5 phosphorylated and phosphorylated  $\tau$  at Ser262  $\tau$ . Skin lysates from 65 subjects were analyzed (HC=20, PD=26, MSA=9, PSP/CBD=10). Considering the two anatomical sites separately, the 6 7 PSP/CBD group showed significantly more  $\tau$  than PD and MSA in cervical skin (Fig. 4A, Supplementary Table 2). No differences were observed between the two anatomical sites within 8 9 groups (Fig. 4A). A higher amount of  $\tau$  considering both locations (compound  $\tau$ ) was found in PSP/CBD than in all other groups (Fig. 4A). Univariate logistic regression analysis (Table 3) 10 showed a significant association of compound  $\tau$  concentration and PSP/CBD diagnosis vs. all 11 other groups [OR 1.94 (CI: 1.18-3.18), p=0.008] and vs. synucleinopathies (MSA/PD) [OR 2.09 12 13 (CI: 1.15-3.82), p=0.01]. This association was still significant after adjusting for age, gender, and LEDD in a multivariate model [OR 7.4 (CI: 1.27-43.950), p=0.02, Table 3]. 14 These results were confirmed by ROC curve analysis; compound  $\tau$  concentration allowed the 15

15 These results were confirmed by ROC curve analysis; compound  $\tau$  concentration allowed the 16 identification of PSP/CBD group *vs.* PD (*P*=0.025, AUC=0.812) and *vs.* MSA (*P*=0.004, 17 AUC=0.900), while for PSP/CBD *vs.* HC, the best performance was obtained by  $\tau$  amount at 18 ankle site (*P*=0.017, AUC=0.774) (Fig. 4B, Supplementary Table 3).

## Skin τ concentration and IENFD stratify subjects according to the clinical diagnosis

IENFD was assessed as a measure of small fiber neuropathy and a marker of neurodegeneration.
While PD and MSA showed a significant reduction of total and ankle IENFD compared to HC
(Table 2), PSP/CBD patients did not present skin denervation compared to HC.

IENFD contributes to the stratification of all groups simultaneously; a linear discriminant analysis model based on  $\tau$  protein expression and IENFD at both sites allowed the separation of subjects according to their clinical diagnosis with 53.8% accuracy (Fig. 4C, Leave-one-out validation 47.7%). In particular, HC could be separated from patients (PD, MSA, PSP/CBD) with 73.8% accuracy (Leave-one-out validation 69.2%) and PSP/CBD from synucleinopathies
with 82.2% accuracy (Leave-one-out validation 77.8%). Of interest, PSP/CBD were
discriminated from PD and MSA with 77.8% and 84.2% accuracy, respectively (Leave-one-out validation 72.2% and 68.4%, respectively).

#### **5** Skin τ concentration correlates with clinical scales

6 In HC, compound and cervical  $\tau$  concentration inversely correlated with age, showing a 7 decrement of the protein with aging (Fig. 5A-B). In MSA, compound concentration directly 8 correlated with COMPASS-31 OH and COMPASS-31 BL, while ankle  $\tau$  directly correlated with 9 COMPASS-31 OH and cervical  $\tau$  with COMPASS-31 BL (Fig. 5C-F). In PSP/CBD, compound 10 and ankle  $\tau$  inversely correlated with MoCa (Fig. 5G-H). No correlations were observed in the 11 PD group.

## 12 **Discussion**

This study demonstrated that  $\tau$  protein is highly expressed in human epidermal somatosensory nerve fibers and cholinergic/adrenergic nerves surrounding dermal autonomic structures, such as SG, MAP, and SbG. In particular, we demonstrated an increased amount of  $\tau$  both at transcript and protein levels in skin biopsies of patients with PSP/CBD tauopathies compared to healthy subjects and patients with PD and MSA. This is of relevance because it highlights that accumulation of  $\tau$  occurs in the peripheral as well as in the central nervous system, and it can be detected in an easily accessible tissue such as skin.

A previous study in abdominal skin biopsy of patients with tauopathies using HT7 antibody 20 against full-length  $\tau$ , demonstrated  $\tau$  immunoreactivity only in autonomic fibers surrounding 21  $SG^{23}$ . The discrepancy is probably explained by technical issues: formalin-fixed and 4-um-thick 22 paraffin-embedded sections were used in the previous study, while we used PLP 2% fixative and 23 24 50-µm sections. Indeed, formalin fixation reduces the integrity of peripheral antigen retrieval and is not suitable for the study of intraepidermal small nerve fibers<sup>45</sup>. Besides, thicker tissue 25 sections are required for adequate skin nerve fibers sampling since a standard paraffin-embedded 26 tissue section provides only a fraction of the tissue volume obtained with a 20–50-mm frozen 27

tissue section<sup>46</sup>. In addition, thin tissue sections, by disrupting the nerve fiber structure, reduce
 the ability to visualize intraneural proteins such as τ<sup>45</sup>.

3 In the skin, by Wb, we detected two bands, at 55kDa and 70 kDa, differently from the human adult brain, which presents six  $\tau$  isoforms<sup>47</sup>. The 55KDa isoform was also observed in 4 abdominal<sup>24</sup> and cervical skin<sup>26</sup>, and in colon mucosa samples<sup>16</sup> and co-migrated with the 0N4R-5 1N3R isoforms expressed in the adult human brain, similarly to what has been demonstrated for 6  $\tau$  in the gastro-enteric system<sup>16</sup>. Indeed, skin and gastro-enteric tissues comprise small nerve 7 fibers encompassing amyelinated somatosensory fibers (epidermis) and thinly myelinated Aδ 8 (dermis and autonomic nervous system), which share anatomical and physiological 9 characteristics with the dopaminergic and cholinergic system, prone respectively to 10 synucleinopathies and tauopathies<sup>17</sup>. The 70kDa band was not previously observed in the skin; 11 however, it was confirmed by a panel of different antibodies, so that it is unlikely unspecific. 12 Consistently with previous evidence<sup>16,24</sup>, we did not detect the peripheral  $\tau$  isoform named "Big-13 tau" at 110KDa<sup>48</sup> in the skin. Big-tau is generated by the incorporation of exon 4a that doubles 14 the N-terminal domain, and allows a greater stabilization and spacing between the microtubules 15 in large diameter peripheral nerves, such as sciatic nerves and central process projecting to the 16 dorsal horn of the spinal cord<sup>49</sup>. Thus, Big-tau is likely absent in skin innervation where small 17 fibers are predominant. 18

The transcript analysis of  $\tau$  revealed the 2N and 4R variants are the most frequent in the skin; we 19 observed mainly the 4R in all groups and the 3R in HC and PD. This is of interest since we know 20 21 that in PSP and CBD, the abnormal  $\tau$  aggregates are composed primarily of 4R isoforms and that in neurodegenerative disease, the ratio of 3R/4R is altered<sup>50</sup>. Of note, quantitative analysis of 22 isoform transcripts showed a major increase of 2N and 4R mRNA in the skin of PSP/CBD 23 compared to the other groups and the healthy brain sample. In physiological conditions, the 2N 24 represents only the 10% of  $\tau$  isoforms in the brain<sup>50</sup> and displays a higher propensity for 25 somatodendritic localization; thus, this increase in the skin axonal compartment looks 26 abnormal<sup>51</sup>. Another study has demonstrated that protein interactors of 2N  $\tau$  isoforms are highly 27 enriched in disease-related pathways<sup>52</sup>. In line with the increased level of the transcript, we also 28 29 demonstrated an increased amount of total  $\tau$  protein in the skin of PSP/CBD, and it is known that the expression level of substrates can amplify the pathogenic seed and contribute to the selected 30 31 vulnerability of different neuronal populations in misfolded protein-associated neurodegenerative

diseases<sup>53,54</sup>. Further, recent evidence suggests that τ can assemble into fibrils and filaments
before post-translational modification, such as phosphorylation and ubiquitination<sup>55</sup>. Beyond
confirming the utility of skin biopsy analysis for diagnostic purposes, these results may have
relevance in terms of mechanisms of disease in tauopathies.

We demonstrated phosphorylated  $\tau$  species in the skin in both HC and patients with 5 neurodegenerative disorders by Wb and not by IF, likely due to the lower sensitivity of IF. In all 6 7 groups, phosphorylated  $\tau$  was more abundant at the cervical site. The presence of phosphorylated  $\tau$  in healthy conditions is consistent with an increasing body of evidence suggesting how  $\tau$ 8 protein can be physiologically regulated by phosphorylation/dephosphorylation processes<sup>4</sup>. 9 Further, phosphorylation at Ser262, Ser396, Ser404 were already demonstrated in non-10 pathological conditions<sup>4,56</sup>. Moreover, it has been observed that  $\tau$  protein freshly isolated from 11 surgical brain tissues presents a more highly phosphorylated state than normal adult human  $\tau$ 12 from autoptic studies due to the intense dephosphorylation activity of the postmortem period and 13 that adult human brain  $\tau$  is phosphorylated at many of the same sites as Alzheimer's disease 14 paired helical filaments<sup>57</sup>. The finding of phosphorylated  $\tau$  in synucleinopathies is not 15 unexpected. In a previous work on postmortem PD striatum, it has been shown that  $\tau$  was 16 hyperphosphorylated at Ser262 among other epitopes<sup>11</sup>, and a more recent one showed that  $\tau$  was 17 hyperphosphorylated at ten epitopes in PD striatum, sharing 50% overlap with Alzheimer's 18 disease<sup>58</sup>. Previous studies showed a greater AT8 (pS202/T205) immunoreactivity in skin 19 biopsies of patients with Alzheimer's disease than HC and with PSP than PD, while no 20 differences were detected with PHF-1 (pSer396/Ser404)<sup>25,26</sup>. We did not find specific pattern of 21 phosphorylation in the skin of PSP/CBD; this is possibly explained by methodological issues, 22 since increased phosphorylated sites are usually detected in insoluble aggregates of  $\tau$  derived 23 24 from brain of patients, while we analyzed the soluble fraction only.

We found a significantly higher concentration of  $\tau$  was measured by ELISA in the skin of PSP/CBD compared to the other groups. Increased  $\tau$  concentration in skin predicted the PSP/CBD diagnosis after adjusting for age, gender and LEDD, and ROC curve analysis demonstrated an optimal performance, especially at the cervical site, in discriminating PSP/CBD from synucleinopathies, PD, and MSA. This is of clinical relevance as discriminating PSP/CBD *vs.* PD and *vs.* MSA is often a challenging task also for movement disorders experts. Furtherly,  $\tau$ protein concentration in skin correlated with cognitive impairment in PSP/CBD.

1 Between the two anatomical sites, cervical skin biopsy showed the largest differences among groups and the highest diagnostic performance. The diagnostic potential of cervical skin biopsy 2 3 in differentiating PD and AP was also demonstrated by measuring a-Synuclein oligomers by proximity ligation  $assay^{22}$ . The cervical area possibly bears the advantage of being anatomically 4 closer to the CNS and brainstem and less exposed to confounders such as peripheral neuropathies 5 that are more frequent in the aging population. This data, taken together, push towards a deeper 6 7 and combined evaluation of  $\tau$  and  $\alpha$ -Synuclein as well as their pathologic forms in cervical skin as a promising diagnostic tool to differentiate misfolding protein-related neurodegenerative 8 disorders. The increased expression of  $\tau$  in skin biopsy of patients with tauopathies is also 9 relevant because it sheds light on possible pathological events occurring in the peripheral 10 nervous system. In supporting a potential role of  $\tau$  in causing peripheral neurodegeneration, a 11 recent work showed that overexpressing human non-mutant  $\tau$  in mice is associated with 12 peripheral neuropathy with somatofugal degeneration<sup>59</sup>. In fact,  $\tau$  plays an important role in 13 stabilizing neuronal microtubules and regulating axonal transport as well as mitochondria 14 homeostasis<sup>17</sup>, and an overexpression/dysfunction may cause axonal degeneration. On the other 15 hand, in this study, we did not find a clear intraepidermal nerve fiber reduction in PSP/CBD, 16 while a small fiber neuropathy was detected in PD and MSA. Thus, it is conceivable that  $\alpha$ -17 Synuclein is associated with a dying-back degeneration while  $\tau$  may be involved in more 18 centrifugal-like neurotoxicity. 19

Limitations of this study are the relatively small number of subjects evaluated and the lack of a 20 postmortem pathological confirmation of the clinical diagnosis. Besides, we analyzed only a few 21 of the numerous phosphorylated epitopes of  $\tau$ , and it would be appropriate to investigate also 22 other post-translation modifications such as acetylation or ubiquitination dysregulation that may 23 have a significant role in pathology<sup>5,6</sup> as well as it would be of interest to analyze insoluble  $\tau$ 24 aggregates in the skin of PSP/CBD and synucleinopathies. Further, we used a custom ELISA 25 26 assay, and for reproducibility in future studies, it would be recommended that commercially available ELISA for Tau would be utilized. However, the strengths of the study are the 27 evaluation of a prospective cohort with a group of healthy, age-matched subjects and the 28 29 exclusion of other concomitant systemic pathologies and possible confounders like dopaminergic treatment. 30

In conclusion, this comprehensive study accurately characterized the presence of τ protein in skin
 biopsies of multiple neurodegenerative disorders. It raises new questions about the pathogenesis
 of tauopathies, but it also shows how skin biopsy is a robust research tool in the field of
 diagnostic biomarkers for neurodegenerative diseases.

## 5 Acknowledgements

6 The authors are very grateful to all the patients and their relatives who participated in this study.

7 They are grateful to Mrs. Nicole Vago and Mrs. Mara Kuster, CTU nurses, for their valuable

8 work on the clinical database.

## 9 Funding

10 The research leading to these results received funding from FIDINAM 05.2020, Parkinson

11 Schweiz and Jacques und Gloria Gossweiler Stiftung.

## 12 **Competing interests**

13 The authors report no competing interests.

## 14 Supplementary material

15 'Supplementary material is available at *Brain* online'.

## 1 References

Andreadis, A. Misregulation of tau alternative splicing in neurodegeneration and 2 1 dementia. Prog Mol Subcell Biol 44, 89-107, doi:10.1007/978-3-540-34449-0\_5 (2006). 3 4 2 Martin, L., Latypova, X. & Terro, F. Post-translational modifications of tau protein: 5 implications for Alzheimer's disease. Neurochem Int 58. 458-471, 6 doi:10.1016/j.neuint.2010.12.023 (2011). 7 3 Morris, M. et al. Tau post-translational modifications in wild-type and human amyloid 8 precursor protein transgenic mice. Nat Neurosci 18, 1183-1189, doi:10.1038/nn.4067 9 (2015). Hanger, D. P., Anderton, B. H. & Noble, W. Tau phosphorylation: the therapeutic 10 4 challenge for neurodegenerative disease. Trends Mol Med 15. 112-119. 11 doi:10.1016/j.molmed.2009.01.003 (2009). 12 Min, S. W. et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. 5 13 14 *Neuron* **67**, 953-966, doi:10.1016/j.neuron.2010.08.044 (2010). Petrucelli, L. et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and 15 6 aggregation. Hum Mol Genet 13, 703-714, doi:10.1093/hmg/ddh083 (2004). 16 7 Alonso, A., Zaidi, T., Novak, M., Grundke-Igbal, I. & Igbal, K. Hyperphosphorylation 17 induces self-assembly of tau into tangles of paired helical filaments/straight filaments. 18 Proc Natl Acad Sci U S A 98, 6923-6928, doi:10.1073/pnas.121119298 (2001). 19 Braak, E., Braak, H. & Mandelkow, E. M. A sequence of cytoskeleton changes related to 20 8 the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87, 554-21 567, doi:10.1007/bf00293315 (1994). 22 9 Grundke-Iqbal, I. et al. Abnormal phosphorylation of the microtubule-associated protein 23 tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913-4917, 24 doi:10.1073/pnas.83.13.4913 (1986). 25 Kovacs, G. G. Tauopathies. Handb Clin Neurol 145, 355-368, doi:10.1016/B978-0-12-26 10 27 802395-2.00025-0 (2017). 11 Wills, J. et al. Elevated tauopathy and alpha-synuclein pathology in postmortem 28 Parkinson's disease brains with and without dementia. Exp Neurol 225, 210-218, 29 doi:10.1016/j.expneurol.2010.06.017 (2010). 30 Rong, Z. et al. Phosphorylated alpha-synuclein and phosphorylated tau-protein in sural 31 12 nerves may contribute to differentiate Parkinson's disease from multiple system atrophy 32 33 and progressive supranuclear paralysis. Neuroscience Letters 756, doi:ARTN 135964 10.1016/j.neulet.2021.135964 (2021). 34 Nagaishi, M., Yokoo, H. & Nakazato, Y. Tau-positive glial cytoplasmic granules in 35 13 36 multiple system atrophy. Neuropathology 31, 299-305, doi:10.1111/j.1440-1789.2010.01159.x (2011). 37 14 38 Arnold, S. E. et al. Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol 67, 462-469, doi:10.1002/ana.21910 (2010). 39 Hattori, H. et al. The tau protein of oral epithelium increases in Alzheimer's disease. J 40 15 Gerontol A Biol Sci Med Sci 57, M64-70, doi:10.1093/gerona/57.1.m64 (2002). 41 Lionnet, A. et al. Characterisation of tau in the human and rodent enteric nervous system 42 16 43 under physiological conditions and in tauopathy. Acta Neuropathol Commun 6, 65, doi:10.1186/s40478-018-0568-3 (2018). 44

- 17 Vacchi, E., Kaelin-Lang, A. & Melli, G. Tau and Alpha Synuclein Synergistic Effect in
   Neurodegenerative Diseases: When the Periphery Is the Core. Int J Mol Sci 21,
   doi:10.3390/ijms21145030 (2020).
- 4 18 Donadio, V. *et al.* Skin nerve alpha-synuclein deposits: a biomarker for idiopathic
  5 Parkinson disease. *Neurology* 82, 1362-1369, doi:10.1212/WNL.00000000000316
  6 (2014).
- 7 19 Doppler, K. *et al.* Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy. *Mov Disord* 30, 1688-1692, doi:10.1002/mds.26293 (2015).
- 9 20 Melli, G. *et al.* Cervical skin denervation associates with alpha-synuclein aggregates in
   10 Parkinson disease. *Ann Clin Transl Neurol* 5, 1394-1407, doi:10.1002/acn3.669 (2018).
- Nolano, M. *et al.* Small fiber pathology parallels disease progression in Parkinson disease: a longitudinal study. *Acta Neuropathol* 136, 501-503, doi:10.1007/s00401-018-1876-1 (2018).
- Vacchi, E. *et al.* Alpha-synuclein oligomers and small nerve fiber pathology in skin are
  potential biomarkers of Parkinson's disease. *npj Parkinson's Disease* 7, 119,
  doi:10.1038/s41531-021-00262-y (2021).
- 1723Dugger, B. N. *et al.* Tau immunoreactivity in peripheral tissues of human aging and18select tauopathies. *Neurosci Lett* 696, 132-139, doi:10.1016/j.neulet.2018.12.031 (2019).
- Dugger, B. N. *et al.* The Presence of Select Tau Species in Human Peripheral Tissues and
  Their Relation to Alzheimer's Disease. *J Alzheimers Dis* 54, 1249, doi:10.3233/JAD169007 (2016).
- 22 25 Rodriguez-Leyva, I. *et al.* Parkinson disease and progressive supranuclear palsy: protein
   23 expression in skin. *Ann Clin Transl Neurol* 3, 191-199, doi:10.1002/acn3.285 (2016).
- 24 26 Rodriguez-Leyva, I. *et al.* Presence of Phosphorylated Tau Protein in the Skin of Patients
   25 with Alzheimer Disease. *Annals of Neurology* 74, S63-S63 (2013).
- 26 27 Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of
  27 idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol*28 *Neurosurg Psychiatry* 55, 181-184, doi:10.1136/jnnp.55.3.181 (1992).
- 29 28 Gilman, S. *et al.* Second consensus statement on the diagnosis of multiple system
  30 atrophy. *Neurology* **71**, 670-676, doi:10.1212/01.wnl.0000324625.00404.15 (2008).
- Hoglinger, G. U. *et al.* Clinical diagnosis of progressive supranuclear palsy: The
   movement disorder society criteria. *Mov Disord* 32, 853-864, doi:10.1002/mds.26987
   (2017).
- 34 30 Armstrong, M. J. *et al.* Criteria for the diagnosis of corticobasal degeneration. *Neurology*35 80, 496-503, doi:10.1212/WNL.0b013e31827f0fd1 (2013).
- 36 31 Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. *Neurology* 37 17, 427-442, doi:10.1212/wnl.17.5.427 (1967).
- Fahn S, E. R., UPDRS program members. Unified Parkinsons Disease Rating Scale. In:
  Fahn S, Marsden CD, Goldstein M, Calne DB, editors. . Recent developments in Parkinsons disease, vol 2. . *Florham Park, NJ: Macmillan Healthcare Information*, 153-156 (1987).
- Folstein, M. F., Folstein, S. E. & McHugh, P. R. "Mini-mental state". A practical method
  for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 12, 189-198,
  doi:10.1016/0022-3956(75)90026-6 (1975).

- 34 Nasreddine, Z. S. *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening
   tool for mild cognitive impairment. *J Am Geriatr Soc* 53, 695-699, doi:10.1111/j.1532 5415.2005.53221.x (2005).
- 4 35 Beck AT, S. R., Brown GK. BDI-II: Beck Depression Inventory Manual. (1996).
- Sletten, D. M., Suarez, G. A., Low, P. A., Mandrekar, J. & Singer, W. COMPASS 31: a
  refined and abbreviated Composite Autonomic Symptom Score. *Mayo Clin Proc* 87, 1196-1201, doi:10.1016/j.mayocp.2012.10.013 (2012).
- 8 37 Stiasny-Kolster, K. *et al.* The REM sleep behavior disorder screening questionnaire A new diagnostic instrument. *Movement Disord* 22, 2386-2393, doi:10.1002/mds.21740
   10 (2007).
- Tomlinson, C. L. *et al.* Systematic Review of Levodopa Dose Equivalency Reporting in
   Parkinson's Disease. *Movement Disord* 25, 2649-2653, doi:10.1002/mds.23429 (2010).
- 39 Vacchi, E., Pinton, S., Kaelin-Lang, A. & Melli, G. Targeting Alpha Synuclein
   Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence
   Assay. J Vis Exp, doi:10.3791/59558 (2019).
- Lauria, G. *et al.* EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral
   neuropathy. *Eur J Neurol* 12, 747-758, doi:10.1111/j.1468-1331.2005.01260.x (2005).
- Lauria, G. *et al.* European Federation of Neurological Societies/Peripheral Nerve Society
  Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of
  a joint task force of the European Federation of Neurological Societies and the Peripheral
  Nerve Society. *Eur J Neurol* 17, 903-912, e944-909, doi:10.1111/j.14681331.2010.03023.x (2010).
- Lauria, G., Lombardi, R., Camozzi, F. & Devigili, G. Skin biopsy for the diagnosis of peripheral neuropathy. *Histopathology* 54, 273-285, doi:10.1111/j.1365-2559.2008.03096.x (2009).
- Provitera, V. *et al.* A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg. *European Journal of Neurology* 23, 333-338, doi:10.1111/ene.12842 (2016).
- Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25, 402-408, doi:10.1006/meth.2001.1262 (2001).
- Gibbons, C. *et al.* Reader Response: In Vivo Distribution of alpha-Synuclein in Multiple
   Tissues and Biofluids in Parkinson Disease. *Neurology* 96, 964-965,
   doi:10.1212/WNL.00000000011941 (2021).
- Gibbons, C. H., Garcia, J., Wang, N., Shih, L. C. & Freeman, R. The diagnostic discrimination of cutaneous alpha-synuclein deposition in Parkinson disease. *Neurology* 87, 505-512, doi:10.1212/WNL.0000000002919 (2016).
- 47 Lee, G., Cowan, N. & Kirschner, M. The primary structure and heterogeneity of tau protein from mouse brain. *Science* 239, 285-288, doi:10.1126/science.3122323 (1988).
- 48 Goedert, M., Spillantini, M. G. & Crowther, R. A. Cloning of a big tau microtubule41 associated protein characteristic of the peripheral nervous system. *Proc Natl Acad Sci U S*42 A 89, 1983-1987, doi:10.1073/pnas.89.5.1983 (1992).
- 43 49 Fischer, I. & Baas, P. W. Resurrecting the Mysteries of Big Tau. *Trends Neurosci* 43, 493-504, doi:10.1016/j.tins.2020.04.007 (2020).

- Limorenko, G. & Lashuel, H. A. Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies. *Chem Soc Rev* 51, 513-565, doi:10.1039/d1cs00127b (2022).
- 4 51 Bachmann, S., Bell, M., Klimek, J. & Zempel, H. Differential Effects of the Six Human
  5 TAU Isoforms: Somatic Retention of 2N-TAU and Increased Microtubule Number
  6 Induced by 4R-TAU. *Front Neurosci* 15, 643115, doi:10.3389/fnins.2021.643115 (2021).
- Liu, C., Song, X., Nisbet, R. & Gotz, J. Co-immunoprecipitation with Tau Isoform-specific Antibodies Reveals Distinct Protein Interactions and Highlights a Putative Role for 2N Tau in Disease. *J Biol Chem* 291, 8173-8188, doi:10.1074/jbc.M115.641902 (2016).
- Peng, C., Trojanowski, J. Q. & Lee, V. M. Protein transmission in neurodegenerative disease. *Nat Rev Neurol* 16, 199-212, doi:10.1038/s41582-020-0333-7 (2020).
- Luna, E. *et al.* Differential alpha-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. *Acta Neuropathol* 135, 855-875, doi:10.1007/s00401-018-1829-8 (2018).
- 16 55 Hasegawa, M. Structure of NFT: Biochemical Approach. *Adv Exp Med Biol* 1184, 23-34,
   17 doi:10.1007/978-981-32-9358-8\_2 (2019).
- Matsuo, E. S. *et al.* Biopsy-derived adult human brain tau is phosphorylated at many of
  the same sites as Alzheimer's disease paired helical filament tau. *Neuron* 13, 989-1002,
  doi:10.1016/0896-6273(94)90264-x (1994).
- 57 Beharry, C. *et al.* Tau-induced neurodegeneration: mechanisms and targets. *Neurosci Bull*30, 346-358, doi:10.1007/s12264-013-1414-z (2014).
- 58 Duka, V. *et al.* Identification of the sites of tau hyperphosphorylation and activation of
  tau kinases in synucleinopathies and Alzheimer's diseases. *PLoS One* 8, e75025,
  doi:10.1371/journal.pone.0075025 (2013).
- Marquez, A. *et al.* Tau associated peripheral and central neurodegeneration:
  Identification of an early imaging marker for tauopathy. *Neurobiol Dis* 151, 105273, doi:10.1016/j.nbd.2021.105273 (2021).
- 29

### **1** Figure legends

2 **Figure 1**  $\tau$  protein in healthy skin. (A) Schematic representation of  $\tau$  protein four domains and 3 binding sites of Abs used for IF. (B) Confocal microscopy images of skin sections from HC stained with axonal markers in red (PGP9.5 and  $\beta$ TubIII) and full-length  $\tau$  markers in green 4 (Tau13, HT7, Tau5, and Tau). For each antibody is shown the staining at the epidermis and 5 6 dermis, sweat gland (SG), sebaceous gland (SbG), and muscle arrector pili (MAP). On the right, 7 enlargement of intraepidermal small fibers (1) and autonomic fibers in SG (2), SbG (3), and MAP (4) showing in yellow the colocalization between Tau (green) and  $\beta$ TubIII (red). (C) IF of 8 skin biopsy from HC showing cholinergic (VIP) and adrenergic innervation (TH) in red and Tau 9 (unphosphorylated and phosphorylated at Ser262 human Tau), in green) in SG (5) and SbG (6). 10 On the right, enlargement showing in yellow the colocalization between Tau (green) and VIP 11 (red, top) and TH (red, bottom). Magnification 40x, scale bar 50µm. Images are representative of 12 13 at least three independent experiments on 8 subjects.

Figure 2  $\tau$  protein in skin in pathological groups. Confocal microscopy images of skin sections from patients with PD, MSA, and PSP/CBD at the ankle and cervical sites. In green unphosphorylated and phosphorylated at Ser262 human Tau and in red  $\beta$ TubIII staining. For each group, images of epidermis and dermis, sweat gland (SG), sebaceous gland (SbG), and muscle arrector pili (MAP) are shown. Magnification 40x, scale bar 50µm. Images are representative of at least three independent experiments in 18 subjects (PD=10, MSA=3, PSP/CBD=5).

Figure 3 Skin  $\tau$  isoforms and phosphorylated  $\tau$ . (A) Schematic representation of  $\tau$  isoforms 21 obtained by alternative splicing of exons 2, 3, and 10 (in green) and 4a (purple) in the human 22 23 nervous system. (B) Representative image of Wb analysis of skin lysates from HC, PD, MSA, 24 and PSP/CBD subjects at the ankle and cervical sites, stained with unphosphorylated and 25 phosphorylated at Ser262 human Tau. Images are representative of at least five independent experiments. (C) PCR analysis of skin lysates from ankle and cervical sites. Images are 26 27 representative of at least five independent experiments. (D) Real-time PCR analysis of MAPTgene, 2N variant (E), and 4R variant (F) of skin lysates at ankle and cervical sites in pathological 28 29 groups compared to the healthy human brain. The amount of RNA was normalized to the expression of the housekeeper *RPL27*. For each group, the mean and SD are reported, and each 30

point represents an experiment. (G) Schematic representation of τ protein four domains and
 binding sites of Abs for phosphorylated τ. (H-K) Representative image of Wb analysis of skin
 lysates from HC, PD, MSA, and PSP/CBD subjects at the ankle and cervical locations, stained
 with Abs against phosphorylated τ. MW: molecular weight.

Figure 4 Diagnostic value of skin  $\tau$  protein concentration. (A) Skin  $\tau$  concentration measured 5 by Elisa assay at both anatomical sites and at each anatomical region in HC and pathologic 6 7 groups. Kruskal-Wallis analysis is shown, data are expressed as median and interquartile ranges. *P*-values < 0.05 were considered significant (\*<0.05, \*\*<0.01). (**B**) ROC curves analysis of  $\tau$ 8 concentration identifying the best cut-off for each parameter. The referral line is reported in grey. 9 For each comparison, the table provides the asymptotic significance, AUC with 95% CI, 10 sensitivity, and specificity for  $\tau$  expression at the ankle, cervical, and both sites. *P*-values < 0.05 11 were considered significant. (C) The canonical plot stratifies patients according to the clinical 12 diagnosis. The model was built considering  $\tau$  concentration and IENFD at the ankle and cervical 13 sites. The plot axes (canonical 1 and canonical 2) were calculated from weighted linear 14 combinations of variables to maximize separation between the four groups. Each subject is 15 represented by a point. HC vs. patients: accuracy 73.8%, Leave-one-out validation 69.2%. 16 PSP/CBD vs. PD: accuracy 77.8%, Leave-one-out validation 72.2%. PSP/CBD vs. MSA 17 accuracy 84.2%, Leave-one-out validation 68.4%. 18

**Figure 5**  $\tau$  protein concentration and clinical scores correlations. Correlations between  $\tau$ protein concentration and age in HC (blue) and between  $\tau$  protein concentration and clinical scales in MSA (orange) and PSP/CBD (green). For each correlation, *P*-value (*P*), Pearson's correlation coefficient (R), regression line (black), and 95% confidence interval (dashed line) are reported.

- \_\_\_
- 24
- 25

#### 1 Table I List of antibodies

News	Turns		Dilution	n Specificity		Communi			
Name	IF Wb ELISA Specificity		Specificity	Company					
Primary									
Tau	Rb pAb	1:1000	1:200	I:500	Unphosphorylated and phosphorylated at Ser262 human Tau	Abcam			
Tau I 3	Ms mAb	1:1000	I:500	-	Unphosphorylated human Tau, aa 2-18	Santa Cruz Biotechnology			
HT7	Ms mAb	1:1000	-	-	Unphosphorylated human Tau, aa 159-163	ThermoFisher Scientific			
Tau5	Ms mAb	1:1000	-	-	Unphosphorylated human Tau, aa 218-225	Abcam			
PS404	Rb pAb	1:500	1:500	-	Tau phosphorylated at Ser404	ThermoFisher Scientific			
p\$262	Rb pAb	1:500	1:500	-	Tau phosphorylated at Ser262	ThermoFisher Scientific			
pThr212	Rb pAb	1.500	1:500	-	Tau phosphorylated at Thr212	ThermoFisher Scientific			
pSer396	Ms mAb	1.500	1:500	-	Tau phosphorylated at Ser396	ThermoFisher Scientific			
PGP9.5	Rb pAb	1:1000	-	-	Axonal marker	Abcam			
βTubIII	Ms mAb	1:500	-	-	Axonal marker	Sigma Aldrich			
TH	Ms mAb	1:200	-	-	Adrenergic nerve fibers	Millipore			
VIP	Rb pAb	1:2000	-	-	Cholinergic nerve fibers	Immunostar			
				S	iecondary	•			
Alexa-Fluor 488	G x Ms	I:400	-	-	AffiniPure Goat Anti-Mouse IgG (H+L)	Jackson ImmunoResearch			
Alexa-Fluor 488	G x Rb	I:400	-		Highly Cross-Adsorbed Goat anti- Rabbit IgG (H+L)	ThermoFisher Scientific			
Alexa-Fluor 594	G x Ms	I:400		- /	Highly Cross-Adsorbed Goat anti- Mouse IgG (H+L)	ThermoFisher Scientific			
Alexa-Fluor 594	G x Rb	1:400	-	- /	AffiniPure Goat Anti-Rabbit IgG (H+L)	Jackson ImmunoResearch			
IRDye® 680RD	G x Ms		1:5000	-	IRDye® 680RD Goat anti-Mouse IgG	LI-COR Biosciences			
IRDye® 800CW	G x Rb		I :5000	_	IRDye® 800CW Goat anti-Rabbit IgG	LI-COR Biosciences			
Anti-Rabbit HRP	G x Rb	1	-	1:5000	Goat anti-Rabbit IgG (H+L)-HRP Conjugate	Bio-Rad			

Characteristics of primary and secondary antibodies used in this study: name, type, dilution for IF, Wb and ELISA assay, specificity, and company. Abbreviations: Rb (Rabbit), pAb (polyclonal Antibody), Ms (Mouse), mAb (monoclonal Antibody), G (Goat), HRP (horseradish peroxidase).

#### 1 Table 2 Demographic data and clinical scores

						Pairwise Comparisons					
	HC [n=24]	PD [n=31]	MSA [n=14]	PSP/CBD [n=15]	Overall P-value	PD vs. HC	MSA vs. HC	PSP/CBD vs. HC	PD vs. MSA	PSP/CBD vs. PD	PSP/CBD vs. MSA
Age (years)	62 ± 8	67 ± 12	67 ± 8	75 ± 6	0.011	0.090	0.105	0.000	0.868	0.094	0.065
Sex (ref. male)	12 (50.0%)	17 (54.8%)	4 (28.6%)	7 (46.7%)	0.433	-	-	-	-	-	<b>.</b>
Disease duration (years)	-	5.0 [3.0– 9.0]	5.0 [1.8– 7.31	4.0 [3.0– 5.0]	0.305	-	-	-	-		•
H&Y	-	2.0 [2.0– 3.01	4.0 [3.0– 5.01	4.0 [3.0– 4.0]	0.000	-	-	-	0.000	0.000	0.377
MDS- UPDRS-I	-	4.0 [2.0– 6.0]	8.0 [6.5– [0.5]	12.0 [6.5– 22.0]	0.006	-	-	-	0.016	0.011	0.310
MDS- UPDRS-II	-	6.0 [5.0– 9.81	15.0 [8.5– 21.0]	17.0 [13.0– 27.51	0.005	-	-		0.050	0.002	0.421
MDS- UPDRS-III	-	17.0 [12.0– 23.31	32.5 [23.0– 46.5]	31.5 [22.5– 41.5]	0.000	-	-	$\langle \mathbf{r} \rangle$	0.003	0.000	0.798
MDS- UPDRS-Total	-	28.5 [20.3– 37.8]	53.0 [31.5– 67.0]	53.0 [39.3– 97 51	0.004	-		<u> </u>	0.050	0.001	0.792
COMPASS- 31 OH	-	0.0 [0.0– [6.0]	0.0 [0.0– 21.0]	0.0 [0.0– 20.0]	0.864	·	-	-	-	-	-
COMPASS- 31 VM	-	0.0 [0.0– 0.0]	0.0 [0.0– 0.01	0.0 [0.0– 0.0]	0.222	<u> </u>	-	-	-	-	-
COMPASS- 31 SM	-	0.0 [0.0– 4.21	2.1 [0.0– 4.21	0.0 [0.0– 4.2]	0.434	-	-	-	-	-	-
COMPASS- 31 GI	-	0.9 [0.0– 6.3]	3.7 [0.0– 5.81	0.0 [0.0– 6.3]	0.697	-	-	-	-	-	-
COMPASS- 31 BL	-	0.0 [0.0– 0.0]	0.5 [0.0– 2.5]	0.0 [0.0– 0.0]	0.003	-	-	-	0.002	0.795	0.050
COMPASS- 31 PM	-	0.0 [0.0– 0.0]	0.0 [0.0– 0.0]	0.0 [0.0– 0.0]	1.000	-	-	-	-	-	-
COMPASS- 31 Total		6.3 [0.8– 24.1]	12.3 [5.5– 27.5]	11.9 [4.2– 28.0]	0.675	-	-	-	-	-	-
BDI-II	- )	6.0 [3.0– 8.5]	8.5 [3.7– 13.0]	14.0 [8.0– 18.0]	0.006	-	-	-	0.238	0.001	0.068
MMSE		30.0 [29.0– 30.0]	28.0 [25.5– 29.0]	26.0 [22.5– 28.0]	0.000	-	-	-	0.004	0.000	0.081
MoCA	-	27.0 [24.0– 29.0]	26.0 [21.5– 27.7]	20.0 [17.0– 24.0]	0.001	-	-	-	0.227	0.000	0.011
Olfactory test	-	7.0 [5.0– 9.0]	9.0 [9.0– 10.8]	7.0 [4.3– 9.8]	0.067	-	-	-	-	-	-
RBD questionnaire	-	3.0 [1.0– 5.3]	3.5 [1.0– 5.2]	2.5 [0.0– 5.0]	0.643	-	-	-	-	-	-
LEDD (mg)	-	495.5 [288.0– 775.0]	437.5 [174.8– 500.01	250.0 [100.0– 451.0]	0.167	-	-	-	-	-	-
IENFD total (Fibers/mm)	4.9 [ 1.5–	10.9 [7.3–	.8 [8.4–	13.5 [7.8– 17.3]	0.044	0.014	0.013	0.214	0.985	0.475	0.497

16.6] 14.8] 13.8]		
IENFD         20.6         14.3         18.1         19.9           cervical         [14.7–         [10.8–         [11.4–         [12.4–         0.288         -         -         -         -           (Fibers/mm)         24.8]         21.5]         21.4]         24.8]         -         -         -         -	-	-
IENFD ankle (Fibers/mm)         9.1         5.7         6.2         6.7 [4.0-         0.029         0.012         0.010         0.082         0.781	0.741	0.604
1 Clinical characteristics of patients. Variables are reported as mean ± SD, median [interquartile range], absolute nu	number (per	centage), as
2 appropriate. A P<0.05 was considered significant and snown in bold.		
5		
Λ	$\sim$	*
		/
5		
6	1	
7		

#### 8 Table 3 T concentration and likelihood of tauopathies diagnosis

		Univari	ate	Multivariate			
		OR (95% CI)	P-value	OR (95% CI)	P-value		
PSP/CBD vs. PD/MSA	Compound τ	2.09 (1.15–3.82)	0.015	7.49 (1.27–43.95)	0.025		
	Age	1.09 (0.99–1.20)	0.050	-	0.111		
	Sex	-	0.525	-	0.057		
	LEDD	-	0.090	-	0.481		

Univariate and multivariate logistic regression analyses were performed to assess the odds ratio (OR) and 95% confidence intervals (95% CI) for T protein at both sites (compound), Age, Sex, and LEDD, between PSP/CBD group and PD/MSA. An OR greater than I indicates an increased likelihood of PSP/CBD diagnosis; P-values < 0.05 were considered significant and shown in bold.

# 9 10 11 12 13

14





Figure 1 174x234 mm (.09 x DPI)









Figure 5 174x234 mm (.09 x DPI)

1